Compare Ryanair Holdings plc (RYAAY) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ryanair Holdings plc vs GeneDx Holdings Corp — how do they compare? Ryanair Holdings plc trades at $54.24 (market cap $27.11B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Ryanair Holdings plc is far larger — about 13.4× GeneDx Holdings Corp's market cap, and Ryanair Holdings plc pays a 1.66% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ryanair Holdings plc for 72 Days and GeneDx Holdings Corp for 19 Days on average.
| RYAAY | WGS | |
|---|---|---|
Market Cap | $27.11B | $2.02B |
Volume | 2,427,380 | 734,640 |
Sector | Industrials | Health |
52-Week High | $73.82 | $167.51 |
52-Week Low | $51.95 | $34.51 |
Typical Hold Time | 72 Days | 19 Days |
Enterprise Value | $24.18B | $2.05B |
Dividend Yield | 1.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RYAAY trades at $54.04, down 3.5% on the day, with a bearish technical signal from moving averages. The company reported revenue of $13.95 billion in 2025 and net income of $1.61 billion, with a P/E ratio of 13.43. Recent earnings have been mixed, with a miss in Q2 2026. News highlights include CEO commentary on Boeing MAX 10 delays and concerns over fuel costs impacting future airfares.
The stock presents a valuation opportunity with low P/E and EV/EBITDA multiples, but faces near-term headwinds from volatile fuel prices and reduced traffic forecasts. Analyst consensus is moderately bullish, with 65% buy ratings, though technical indicators suggest caution. Key risks include oil price sensitivity and competitive pressures in the European airline sector.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
